The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
作者信息
Le Garff-Tavernier Magali, Herbi Linda, de Romeuf Christophe, Azar Nabih, Roos-Weil Damien, Bonnemye Patrick, Urbain Rémi, Leblond Véronique, Merle-Beral Hélène, Vieillard Vincent
机构信息
Sorbonne Universités, UPMC, Univ Paris 06, Paris INSERM U1135, CIMI-Paris AP-HP, Hôpital Pitié-Salpêtrière, Service d'Hématologie Biologique, Paris
Sorbonne Universités, UPMC, Univ Paris 06, Paris INSERM U1135, CIMI-Paris Laboratoire Français de Fractionnement et des Biotechnologies (LFB), Les Ulis.
出版信息
Haematologica. 2015 Apr;100(4):e147-51. doi: 10.3324/haematol.2014.118083. Epub 2014 Dec 31.
Abstract
摘要
相似文献
1
The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
Haematologica. 2015 Apr;100(4):e147-51. doi: 10.3324/haematol.2014.118083. Epub 2014 Dec 31.
2
Selective loss of lymphoid component simulating myeloma in lymphoplasmacytic lymphoma treated with rituximab.
Br J Haematol. 2013 May;161(4):460. doi: 10.1111/bjh.12307. Epub 2013 Mar 26.
3
Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome.
Am J Hematol. 2015 Aug;90(8):E152-3. doi: 10.1002/ajh.24059. Epub 2015 May 29.
4
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Semin Oncol. 1999 Oct;26(5 Suppl 14):97-106.
5
Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.
Blood. 2013 Jun 6;121(23):4694-702. doi: 10.1182/blood-2013-02-482570. Epub 2013 Apr 23.
6
Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
Leuk Lymphoma. 2010 Oct;51(10):1767-70. doi: 10.3109/10428194.2010.509455.
7
B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Exp Hematol. 2010 Mar;38(3):213-21. doi: 10.1016/j.exphem.2009.12.007. Epub 2010 Jan 6.
8
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.
Blood. 2015 Jan 29;125(5):762-6. doi: 10.1182/blood-2014-10-569244. Epub 2014 Dec 10.
9
Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
MAbs. 2014;6(5):1300-13. doi: 10.4161/mabs.32106. Epub 2014 Oct 30.
10
Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Leukemia. 2011 Jan;25(1):101-9. doi: 10.1038/leu.2010.240. Epub 2010 Oct 26.
引用本文的文献
1
Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies.
Cells. 2020 Jun 29;9(7):1578. doi: 10.3390/cells9071578.
2
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
Br J Haematol. 2017 Apr;177(2):243-253. doi: 10.1111/bjh.14534. Epub 2017 Feb 21.
3
Improving natural killer cell cancer immunotherapy.
Curr Opin Organ Transplant. 2015 Dec;20(6):671-80. doi: 10.1097/MOT.0000000000000243.
本文引用的文献
1
Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease.
Front Immunol. 2013 Dec 9;4:422. doi: 10.3389/fimmu.2013.00422.
2
Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion.
Leukemia. 2014 Jan;28(1):230-3. doi: 10.1038/leu.2013.240. Epub 2013 Aug 20.
3
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
J Clin Oncol. 2013 Jan 20;31(3):301-7. doi: 10.1200/JCO.2012.44.7920. Epub 2012 Dec 10.
4
Choice of therapy for patients with Waldenstrom macroglobulinemia.
J Clin Oncol. 2013 Jan 20;31(3):291-3. doi: 10.1200/JCO.2012.46.6177. Epub 2012 Dec 10.
5
Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.
Clin Dev Immunol. 2012;2012:421702. doi: 10.1155/2012/421702. Epub 2012 Aug 1.
6
Natural killer cell immune escape in acute myeloid leukemia.
Leukemia. 2012 Sep;26(9):2019-26. doi: 10.1038/leu.2012.87. Epub 2012 Mar 26.
7
Targeting natural killer cells and natural killer T cells in cancer.
Nat Rev Immunol. 2012 Mar 22;12(4):239-52. doi: 10.1038/nri3174.
8
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
Blood. 2011 May 12;117(19):5019-32. doi: 10.1182/blood-2011-01-293050. Epub 2011 Feb 7.
9
Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Leukemia. 2011 Jan;25(1):101-9. doi: 10.1038/leu.2010.240. Epub 2010 Oct 26.
10
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education.
Blood. 2010 Nov 11;116(19):3853-64. doi: 10.1182/blood-2010-04-281675. Epub 2010 Aug 9.
Zotero 插件